[1] Yamaguchi T, Sugimoto T. New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis[J]? Clin Calcium, 2009, 19(1):38-43. [2] Goss A, Bartold M, Sambrook P, et al. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series[J]. J Oral Maxillofac Surg, 2010, 68(2):337-343. [3] Tardast A, Sjöman R, Løes S, et al. Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking[J]. J Appl Oral Sci, 2015 ,23(3):310-314. [4] Jang HW, Kim JW, Cha IH. Development of animal model for Bisphosphonates-related osteonecrosis of the jaw (BRONJ)[J]. Maxillofac Plast Reconstr Surg, 2015, 37(1):18. [5] Dannemann C, Grätz KW, Riener MO, et al. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder[J]. Bone, 2007,40(4):828-834. [6] Chapurlat RD. Treatment of osteoporosis with annual IV zoledronic acid:effects on hip fracture[J]. Ther Clin Risk Manag, 2009 ,5(2):169-175. [7] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117. [8] Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research[J]. J Bone Miner Res, 2007 , 22(10):1479-1491. [9] Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment[J]. Lancet Oncol, 2006, 7(6):508-514. [10] 宿玉成. 口腔种植学[M]. 2版, 北京: 人民卫生出版社, 2014:135. [11] Chesnut CH , Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis[J]. J Bone Miner Res, 2004 ,19(8):1241-1249. [12] Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure[J]. J Oral Maxillofac Surg, 2010,68(2):243-253. [13] Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity[J]? Bone, 2007,40(3):318-320. [14] American Association of 0ral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteorlecrosis of the jaws[J]. J 0ral Maxillofac Surg,2007,65(3):369-376. [15] Mozzati M, Arata V, Giacomello M, et al. Failure risk estimates after dental implants placement associated with plasma rich in growth factor-Endoret in osteoporotic women under bisphosphonate therapy[J]. J Craniofac Surg, 2015, 26(3):749-755. |